Biofrontera AG

Notice of First Quarter Results 2015

Biofrontera AG / Biofrontera AG: Notice of First Quarter Results 2015 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Leverkusen, Germany, 22 May 2015 - Biofrontera AG (AIM: B8F), the European biopharmaceutical company, will be announcing its results for the first three months period ending 31 March 2015 on 29 May 2015.
There is a conference call for shareholders and interested investors on 29 May 2015 at the following times:

9.00am CET (8.00am UK) conference call in German:
Dial-in number: [phone]
Room number: 24938840#

10.00am CET (9.00am UK) conference call in English:
Dial-in number: [phone]
Room number: 52406056#

Ends

Enquiries, please contact:

Biofrontera AG Prof. Hermann Lübbert, Chief Executive Officer Thomas Schaffer, Chief Financial Officer	[phone] [e-mail] www.biofrontera.com
IR Germany: Brainwell Asset Solutions Jürgen Benker	[phone]
Nomad and Broker: Shore Capital Bidhi Bhoma / Toby Gibbs	[phone]
IR UK: Seton Services Toni Vallen	[phone]
Financial PR: Gable Communications John Bick	[phone] [phone]

Background:

The Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz^®, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz^® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.